CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 99 enrolled
Drug / intervention
CV2CoV (2 µg) +5 morebiological
Likely dose
CV2CoV (2 µg)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05260437
NCT05260437Phase 1Completed
CompareCT.gov

A Phase 1, Open-label, Safety, Reactogenicity, and Immunogenicity Trial of the CV2CoV mRNA Vaccine Against SARS CoV 2 in Seropositive Adult Participants

GlaxoSmithKline·interventional·Posted Mar 2, 2022·Updated Aug 12, 2024

In Brief

A Phase 1 clinical trial evaluating CV2CoV (2 µg), CV2CoV (4 µg), and 4 other interventions for COVID-19 and SARS-CoV-2. Completed, enrolled 99 participants across 24 sites.

Detailed Summary

Prevention of COVID-19 caused by SARS-CoV-2.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19, SARS-CoV-2
CountriesUnited States
CollaboratorsCureVac

Timeline

Phase 1CompletedFinished
2023202420252026
First PostedMar 2, 2022
Enrollment StartMar 24, 2022
Primary CompletionMar 7, 2023
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 4.3 years ago

Interventions

CV2CoV (2 µg)biological

Study vaccine was administered as a single intramuscular injection.

CV2CoV (4 µg)biological

Study vaccine was administered as a single intramuscular injection.

CV2CoV (8 µg)biological

Study vaccine was administered as a single intramuscular injection.

CV2CoV (12 µg)biological

Study vaccine was administered as a single intramuscular injection.

CV2CoV (16 µg)biological

Study vaccine was administered as a single intramuscular injection.

CV2CoV (20 µg)biological

Study vaccine was planned to be administered intramuscularly. No vaccine was administered in the CV2CoV (20 µg) Group, since there were no participants enrolled in it.